Cel­lec­tis shifts CAR-T man­u­fac­tur­ing in-house, boosts ef­fi­ca­cy com­pared to third-par­ty CD­MOs: #ASH23 

Al­lo­gene­ic CAR-T biotech Cel­lec­tis took its CAR-T man­u­fac­tur­ing in-house af­ter fac­ing “bro­ken” sup­ply chain is­sues with third par­ty man­u­fac­tur­ers, and, ac­cord­ing to the com­pa­ny, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER